Vincerx Pharma Statistics
Total Valuation
Vincerx Pharma has a market cap or net worth of 26,171. The enterprise value is -4.41 million.
| Market Cap | 26,171 |
| Enterprise Value | -4.41M |
Important Dates
The next estimated earnings date is Wednesday, November 12, 2025.
| Earnings Date | Nov 12, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
Vincerx Pharma has 5.23 million shares outstanding. The number of shares has increased by 135.37% in one year.
| Current Share Class | 5.23M |
| Shares Outstanding | 5.23M |
| Shares Change (YoY) | +135.37% |
| Shares Change (QoQ) | +59.85% |
| Owned by Insiders (%) | 5.61% |
| Owned by Institutions (%) | 0.37% |
| Float | 4.67M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| PB Ratio | 0.01 |
| P/TBV Ratio | 0.01 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | 0.19 |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 1.79
| Current Ratio | 1.79 |
| Quick Ratio | 1.69 |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -3,136.43% and return on invested capital (ROIC) is -850.36%.
| Return on Equity (ROE) | -3,136.43% |
| Return on Assets (ROA) | -197.53% |
| Return on Invested Capital (ROIC) | -850.36% |
| Return on Capital Employed (ROCE) | -1,206.15% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -1.74M |
| Employee Count | 13 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -99.93% in the last 52 weeks. The beta is 1.68, so Vincerx Pharma's price volatility has been higher than the market average.
| Beta (5Y) | 1.68 |
| 52-Week Price Change | -99.93% |
| 50-Day Moving Average | 0.04 |
| 200-Day Moving Average | 0.42 |
| Relative Strength Index (RSI) | 23.73 |
| Average Volume (20 Days) | 55,518 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | 0.93 |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -24.92M |
| Pretax Income | -22.65M |
| Net Income | -22.65M |
| EBITDA | -24.87M |
| EBIT | -24.92M |
| Earnings Per Share (EPS) | -8.98 |
Balance Sheet
The company has 4.44 million in cash and n/a in debt, giving a net cash position of 4.44 million or 0.85 per share.
| Cash & Cash Equivalents | 4.44M |
| Total Debt | n/a |
| Net Cash | 4.44M |
| Net Cash Per Share | 0.85 |
| Equity (Book Value) | 2.07M |
| Book Value Per Share | 0.39 |
| Working Capital | 2.07M |
Cash Flow
| Operating Cash Flow | -22.84M |
| Capital Expenditures | n/a |
| Free Cash Flow | n/a |
| FCF Per Share | n/a |
Margins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
Vincerx Pharma does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -135.37% |
| Shareholder Yield | -135.37% |
| Earnings Yield | -86,527.07% |
| FCF Yield | n/a |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
The last stock split was on January 28, 2025. It was a reverse split with a ratio of 0.05.
| Last Split Date | Jan 28, 2025 |
| Split Type | Reverse |
| Split Ratio | 0.05 |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | 1 |